Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CeNeRx Biopharma Licenses Cannabinoid Compounds To Study For CNS Indications

This article was originally published in The Pink Sheet Daily

Executive Summary

First clinical candidate anticipated in “a year or two,” company tells “The Pink Sheet” DAILY.

You may also be interested in...



Organon Acquires Large-Molecule Cannabinoid Receptor Agonist Technology From Kadmus

Kadmus’ large-molecule approach dovetails with Organon’s small-molecule work to develop drug candidates based on fatty acid amide hydrolase technology, Organon exec David Nicholson tells “The Pink Sheet” DAILY.

Organon Acquires Large-Molecule Cannabinoid Receptor Agonist Technology From Kadmus

Kadmus’ large-molecule approach dovetails with Organon’s small-molecule work to develop drug candidates based on fatty acid amide hydrolase technology, Organon exec David Nicholson tells “The Pink Sheet” DAILY.

Sanofi’s Zimulti Goes To Advisory Committee

FDA’s Endocrinologic & Metabolic Drugs Advisory Committee will review the obesity agent, formerly known as Acomplia, June 13.

Related Content

Topics

UsernamePublicRestriction

Register

PS066111

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel